February 5, 2008
SpeculatingStocks.com Stock Pick: Curis, Inc. (CRIS)
Stock Price: $1.44
Curis, Inc. is a drug development company committed to leveraging its innovative signaling pathway drug technologies in seeking to create new medicines, primarily for cancer. In expanding its drug development efforts in the field of cancer through its Targeted Cancer Drug Development Platform, the Company is building upon its experiences in targeting signaling pathways in the areas of cancer, neurological disease and cardiovascular disease.
CRIS is involved in stem cells through development work modulating key regulatory signaling pathways which control the repair and regeneration of human tissues and organs. CRIS received a lot of attention earlier this year moving CRIS from the $1.00 level to above $1.60.
CRIS is now at the $1.40 level and appears ready for another step higher in its uptrend. CRIS has been under heavy accumulation over the last month.
The company collaborates with Genentech, Procter & Gamble, and Wyeth.
CRIS is trading at a market cap of only around $90.96 million. CRIS has a strong balance sheet with $41.09 in cash, cash equivalents and short-term investments and no long-term debt.